Hepatitis A Virus (HAV) Antibody, Total

Also known as: anti-HAV, Antibody to Hepatitis A Virus, HAV

Clinical Use

Use

This assay is used to detect total antibodies (IgG and IgM) against Hepatitis A virus (HAV) and may be helpful when assessing HAV immunity. The detection of total antibodies cannot differentiate between vaccination, previously resolved infection, or active infection. If active hepatitis A infection is suspected, HAV IgM testing should be performed. Hepatitis A is a vaccine-preventable disease of the liver caused by the Hepatitis A virus (HAV). HAV is transmitted via the fecal-oral route, usually from direct person-to-person contact or consumption of contaminated food or water. Hepatitis A is an acute, self-limited disease that does not result in chronic infection. HAV IgG antibodies produced in response to vaccination and/or HAV infection persist for life and protect against reinfection.

Special Instructions

Not provided.

Limitations

This assay has not been FDA cleared or approved for the screening of blood or plasma donors. Assay performance characteristics have not been established for immunocompromised or immunosuppressed individuals. This assay does not differentiate IgG and IgM. The performance characteristics of this assay have not been determined for use in cadaveric specimens.

Test Details

Methodology

Immunoassay (CLIA)

Biomarkers

HAV Total Antibody

Analyte

Other

Other • Binary (Detected / Not Detected)

LOINC Codes

Order Codes

13951-9 - HAV Ab Ser Ql IA

Result Codes

13951-9 - HAV Ab Ser Ql IA

Result Turnaround Time

1-2 days

Specimen

Serum

Volume

1 mL

Minimum Volume

0.4 mL

Container

Gel-barrier tube, red-top tube or serum transfer tube

Collection Instructions

If tube other than a gel-barrier tube is used, transfer separated serum to a screw-cap polypropylene transport tube. Do not freeze gel-barrier tube (pour off serum first).